The U.S. Food and Drug Administration on Friday approved labeling changes for Johnson & Johnson and its partner Legend ...

BMS, which already has two FDA-approved CAR T-cell therapies, is eyeing entry into the growing in vivo market.

Bristol Myers Squibb has ended the week with an agreement to buy Orbital Therapeutics – a developer of in vivo cell therapies ...

The deal expands Bristol Myers Squibb's CAR T-cell immunotherapy portfolio with Orbital's lead experimental candidate, ...

Kelley L. Julian, PharmD, BCOP, discusses optimizing MM care, addressing barriers in access to intravenous immunoglobulin and innovative therapies at Huntsman Cancer Institute.

Investor reaction to the deal was muted, with BMO Capital Markets analysts saying they "continue to look for more" from ...

Orbital is developing so-called in vivo CAR-T treatments, which are effective at treating certain blood cancers, but are ...

According to data from KFF, 20% of all claims across Affordable Care Act marketplace plans were denied in 2023. ACA plans covered more than 20 million Americans at the start of 2025. Audits have found ...

Here is our Top Docs 2025 profile on Jeffrey Zonder, M.D., who is part of the Karmanos Cancer Institute’s Multiple Myeloma and Amyloidosis Multidisciplinary Team.

In a historic leap for biotech in Africa, Pretoria-based Altera Biosciences has secured R29 million in pre-seed funding to ...

Scientists have identified an unusual type of brain cell that may play a vital role in progressive multiple sclerosis (MS), ...

These results support the view that a considerable proportion of cancers arise from stochastic processes, rather than being solely driven by hereditary factors or environmental exposures,” the ...